About the Company
a biotech company with a mission to accelerate humanity’s transition to the "age of immunity", we are the business busily decoding the human immune system.
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ADTX News
Aditxt, Inc. Restructures Debt Post-Merger with Evofem
Aditxt, Inc. (ADTX) has released an update to notify the public and investors about an entry into a material definitive agreement. Aditxt, Inc. has been actively restructuring its financial ...
Aditxt CEO Provides Short-Term Loan to Bolster Stability
Aditxt, Inc. (ADTX) has released an update. Amro Albanna, CEO of Aditxt, Inc., provided a $30,000 loan to the company on February 7, 2024, with a generous 8.5% annual interest rate, to be repaid ...
Aditxt Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Client Profile: Aditxt Inc
A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple ...
ADITXT INVESTOR ALERT - Kuznicki Law PLLC Investigates Aditxt, Inc. - ADTX
Kuznicki Law PLLC is investigating the proposed sale of AiPharma Group Ltd. to Aditxt, Inc. (“the Company”) (NasdaqCM: ADTX). Under the terms of the proposed transaction, Aditxt will first ...
Aditxt, Inc. (ADTX) stock price, news, quote & history – Yahoo Finance
RICHMOND, Va., January 30, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced ...
Form 8-K - Current report
ADTX Aditxt Inc Form 8-K - Current report false 0001726711 0001726711 2024-02-26 2024-02-26 iso4217:USD xbrli:shares ... Monitor Book Fórum Rankings ...
ATXI Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product ...
Loading the latest forecasts...